Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Breast cancer gene discovery.

Kornelia Polyak1

  • 1Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney St, Boston, MA 02115, USA. Kornelia_Polyak@dfci.harvard.edu

Expert Reviews in Molecular Medicine
|February 28, 2004
PubMed
Summary

Identifying new breast cancer genes is crucial, as BRCA1 and BRCA2 mutations account for only a small fraction of cases. Further research into genetic and epigenetic factors is needed to understand breast cancer development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESR1 mutations and CDK4/6 inhibitor choice shape clonal selection and adaptive cell states during acquired resistance.

Genome medicine·2026
Same author

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancer.

Journal of the National Cancer Institute·2026
Same author

Whole-genome doubling drives immune evasion by silencing antigen presentation.

Cancer cell·2026
Same author

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Cancer cell·2026
Same author

HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies.

Cancer discovery·2026
Same author

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.

Proceedings of the National Academy of Sciences of the United States of America·2026

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Significant advancements in understanding breast cancer molecular pathology have occurred.
  • High-penetrance genes BRCA1 and BRCA2 have been identified, but explain only ~5% of breast carcinomas.
  • The genetic basis for the majority of breast cancer cases remains largely unknown.

Purpose of the Study:

  • To highlight the need for identifying additional breast cancer susceptibility genes.
  • To emphasize the role of genetic heterogeneity and low-penetrance genes in breast cancer.
  • To underscore the potential of genomic technologies in discovering novel breast cancer genes.

Main Methods:

  • Review of recent advances in breast cancer molecular understanding.
  • Discussion of identified high-penetrance genes (BRCA1, BRCA2).
  • Consideration of candidate low-penetrance genes and epigenetic alterations.

Main Results:

  • Germline mutations in BRCA1 and BRCA2 explain a minority of breast cancer cases.
  • Additional high-to-moderate-penetrance genes likely exist, each responsible for subsets of cases.
  • Epigenetic changes and numerous low-penetrance genes are implicated in breast cancer pathobiology.

Conclusions:

  • Novel genomic technologies and the human genome sequence are powerful tools for identifying new breast cancer genes.
  • Further research is essential to identify genes contributing to the majority of breast cancer cases.
  • Understanding genetic and epigenetic factors is key to unraveling breast cancer tumorigenesis.

Related Experiment Videos